Dublin, Feb. 21, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays - Technologies, Markets and Companies" to their offering.
This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA. Separate chapters are devoted to protein biochips/microarrays, microfluidics and nanobiotechnology-based nano-arrays.
Various applications of biochips and microarrays are described throughout the report. Areas of application such as point-of-care, genetic screening, cancer, and diagnosis of infections are included. Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine
The report provides current share of each segment: market size in 2016 and projected value for the years 2021 and 2026. Gene expression has the largest share and is an established market. Share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics. The growth in protein microarrays is somewhat less, partly because it is more mature than the other submarkets and has already shown considerable growth in the past. Impact of next generation sequencing on segments of microarray markets is identified. Customer requirements and unmet needs are described. Markets are also analyzed according to geographical areas.
Brief profiles of companies involved in biochip/microarray technologies are provided. Currently selected 92 companies are included along with listing of 120 collaborations between companies. The text is supplemented by 21 tables, 11 figures and 140 references to literature.
Key Topics Covered:
Executive Summary
1. Introduction
2. Biochip and Microarray Technologies
3. Microfluidics-based Biochips and Microarrays
4. Protein Biochips
5. Nanobiotechnology-based Biochips & Microarrays
6. Biochips & Microarrays for Epigenetics
7. Applications of Microarrays in Drug Discovery & Development
8. Biochips for Biomarkers, Molecular Diagnostics & Personalized
9. Markets
10. Companies
11. References
For more information about this report visit http://www.researchandmarkets.com/research/d2np4r/biochips_and
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 



